Merck expects no writedowns for Zetia, Vytorin cholesterol drugs

(Reuters) - Merck & Co on Monday said long-awaited data from an 18,000-patient trial suggest the company will not have to write down the value of its blockbuster Zetia and Vytorin cholesterol drugs.

Source: Reuters: Health - November 10, 2014 Category: Consumer Health News Tags: healthNews Source Type: news